780 related articles for article (PubMed ID: 25546673)
1. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
3. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA; Khuri FR; Garon EB; Ramalingam SS
Cancer; 2016 Mar; 122(5):766-72. PubMed ID: 26695526
[TBL] [Abstract][Full Text] [Related]
4. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T
BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136
[TBL] [Abstract][Full Text] [Related]
5. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
6. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
7. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
[TBL] [Abstract][Full Text] [Related]
9. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
10. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
[TBL] [Abstract][Full Text] [Related]
11. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
13. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women.
Tilch E; Seidens T; Cocciardi S; Reid LE; Byrne D; Simpson PT; Vargas AC; Cummings MC; Fox SB; Lakhani SR; Chenevix Trench G
Breast Cancer Res Treat; 2014 Jan; 143(2):385-92. PubMed ID: 24318467
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
15. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
[TBL] [Abstract][Full Text] [Related]
16. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
[TBL] [Abstract][Full Text] [Related]
17. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
[TBL] [Abstract][Full Text] [Related]
18. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
19. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients.
Tong L; Yang XX; Liu MF; Yao GY; Dong JY; Ye CS; Li M
Asian Pac J Cancer Prev; 2012; 13(11):5599-603. PubMed ID: 23317280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
